Ovarian Cancer Drug Approval Highlights AJPB Week in Review

Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.

Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.

Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.

New warnings cover every GLP-1 RA, including semaglutide, tirzepatide, and orforglipron.

At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.

The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.

Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.

The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.